Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
Table 1
Patient demographics and baseline characteristics.
Variable
Double-blind treatment phase
Pomaglumetad methionil
Aripiprazole
Total
valuea
Sex
Female, (%)
185 (36.2)
55 (34.2)
240 (35.7)
0.706
Male, (%)
326 (63.8)
106 (65.8)
432 (64.3)
Age
Mean, year (SD)
42.29 (10.86)
42.95 (10.95)
42.45 (10.88)
0.500
Range, year
18.4–64.4
21.3–65.0
18.4–65.0
Ethnicity, (%)
Hispanic or Latino
73 (14.3)
23 (14.3)
96 (14.3)
>0.999
Not Hispanic or Latino
438 (85.7)
138 (85.7)
576 (85.7)
Race, (%)
American Indian or Alaskan Native
6 (1.2)
0 (0.0)
6 (0.9)
0.130
Asian
3 (0.6)
0 (0.0)
3 (0.4)
Black or African American
238 (46.6)
64 (39.8)
302 (44.9)
Multiple
5 (1.0)
4 (2.5)
9 (1.3)
White
259 (50.7)
93 (57.8)
352 (52.4)
Weight
Mean, kg (SD)
89.8 (22.04)
90.18 (22.80)
89.90 (22.21)
0.851
BMI
Mean, kg/m2 (SD)
30.35 (7.32)
30.72 (7.63)
30.44 (7.39)
0.575
Waist circumference
Mean, cm (SD)
100.90 (16.82)
101.80 (18.01)
101.11 (17.10)
0.559
value is from Fisher’s exact test for categorical data and is from a single-factor analysis of variance model (ANOVA) with fixed effect of treatment for continuous variable. BMI: body mass index; cm: centimeter; : total number of patients in each treatment group; : number of patients in each category; kg: kilogram; kg/m2: kilogram per square meter; SD: standard deviation.
